Independent laboratory journal

Peptide science, measured carefully.

Independent analysis of peptide science, lab protocols, and biomedical research.

Analytical note 01

What HPLC can—and cannot—tell a laboratory

A practical reading guide for chromatograms and Certificates of Analysis.

High-performance liquid chromatography, or HPLC, is an analytical technique used to separate components in a sample. A prepared sample moves through a column with a liquid mobile phase. Differences in how components interact with the column cause them to emerge at different retention times.

The detector response is plotted as a chromatogram. Each peak represents a detected component under the stated method conditions. Peak area can support a relative purity calculation, but the number is meaningful only alongside the method, integration rules, detection wavelength, sample preparation, and system-suitability data.

Purity is not identity

A large principal peak does not, by itself, establish molecular identity. Co-eluting material may be hidden within a peak, and some impurities may respond differently at a selected wavelength. Orthogonal methods such as mass spectrometry or amino-acid analysis address different questions. Strong analytical records show how multiple measurements fit together rather than treating one percentage as a complete characterization.

Reading a Certificate of Analysis

A useful certificate connects a reported result to a defined sample and a documented method. When reviewing one, look for the following:

01
Sample traceability. A lot or sample identifier should connect the certificate to the material examined.
02
Method context. Column chemistry, mobile-phase program, detector, wavelength, and run conditions should be identifiable.
03
Acceptance criteria. The document should distinguish a measured value from a specification or reporting threshold.
04
Chromatographic evidence. A labeled chromatogram, retention-time scale, and transparent peak integration provide context for the summary number.
05
Identity testing. The certificate should state whether identity was assessed separately and which analytical method was used.
06
Laboratory record. Dates, review status, and laboratory attribution help establish who performed and reviewed the work.

Why independent testing matters

Separation between the source of a sample and the laboratory evaluating it can reduce conflicts in reporting. Independence does not guarantee a correct result; method suitability, reference standards, chain of custody, and documentation still determine how much confidence a result deserves. The core question is not whether a certificate exists, but whether its evidence is sufficient for the stated analytical purpose.

Methods primer

How solid-phase peptide synthesis works

In solid-phase peptide synthesis, the growing chain is attached to an insoluble resin. Repeated chemical cycles add protected amino-acid building blocks in a controlled order. The support allows soluble reagents and by-products to be washed away between cycles.

Anchor. The first protected building block is connected to a solid support.
Deprotect. A temporary protecting group is removed to expose the next reactive site.
Couple. The following building block is activated and joined to the growing chain.
Repeat. Deprotection, coupling, and washing continue according to the intended sequence.
Release. The assembled chain is separated from the support and permanent side-chain protection is removed.
Characterize. Purification and complementary analytical methods are used to assess the resulting material.

“Research-grade” is a supplier category, not a universal analytical standard. Pharmaceutical manufacture operates within defined quality systems, validated processes, specifications, and regulatory controls. A label alone does not establish equivalence between those contexts.

Research governance

Ethical boundaries begin before the experiment

Legitimate research begins with a defined question, an appropriate model, documented oversight, and a plan for handling uncertainty. The intended use of a material should be consistent across the protocol, laboratory records, public description, and actual conduct.

Preclinical observations do not establish outcomes in people. Differences in species, model design, exposure, endpoints, and study quality limit translation. Responsible writing makes those limits visible and avoids turning preliminary findings into personal guidance.

Clear boundaries also protect data quality. Training records, instrument logs, sample identifiers, deviation reports, and version-controlled methods make work auditable. Ethical practice is not a disclaimer added at publication; it is part of the research design.

Regulatory watch / 2026

Context determines intended use

A December 2025 FDA warning letter restated a practical point for online research-material publishing: a “research only” label does not control the agency’s intended-use analysis when surrounding website content indicates use as a drug for people.

For analytical work, FDA’s March 2024 adoption of ICH Q2(R2) frames validation around whether an analytical procedure is fit for its intended purpose. Specificity, accuracy, precision, range, and other characteristics are evaluated according to the measurement objective rather than treated as a universal checklist.

This publication offers no products, purchase path, individual-use guidance, or medical claims. Regulatory summaries are editorial and should not be read as legal advice.

Reference desk

Primary reading and guidance

Merrifield, R. B. “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide.” Journal of the American Chemical Society 85 (1963): 2149–2154. DOI: 10.1021/ja00897a025.
Behrendt, R., White, P., and Offer, J. “Advances in Fmoc Solid-Phase Peptide Synthesis.” Journal of Peptide Science 22 (2016): 4–27. DOI: 10.1002/psc.2836.
Lian, Z., Wang, N., Tian, Y., and Huang, L. “Characterization of Synthetic Peptide Therapeutics Using Liquid Chromatography–Mass Spectrometry: Challenges, Solutions, Pitfalls, and Future Perspectives.” Journal of the American Society for Mass Spectrometry 32 (2021): 1852–1860. DOI: 10.1021/jasms.0c00479.
McCarthy, D., Han, Y., Carrick, K., et al. “Reference Standards to Support Quality of Synthetic Peptide Therapeutics.” Pharmaceutical Research 40 (2023): 1317–1328. DOI: 10.1007/s11095-023-03493-1.
U.S. Food and Drug Administration. Q2(R2) Validation of Analytical Procedures. Final Guidance for Industry, March 2024. Docket FDA-2022-D-1503.
U.S. Food and Drug Administration. Warning Letter MARCS-CMS 719337, December 12, 2025. Content current December 23, 2025.